Marie Louise Ndzie Noah

Marie Louise Ndzie Noah

Auto-generated profile, based on publicly available information

Marie Louise Ndzie Noah

Department of Physiology, Xuzhou Medical University, Xuzhou, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2021 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
JAJoseph Adu-Amankwaah
Joseph Adu-Amankwaah
GAGabriel Komla Adzika
Gabriel Komla Adzika
AAAdebayo Oluwafemi Adekunle
Adebayo Oluwafemi Adekunle
MNMarie Louise Ndzie Noah
Marie Louise Ndzie Noah
RMRichard Mprah
Richard Mprah
HSHong Sun
Hong Sun
Due to its reversible nature, Takotsubo cardiomyopathy (TTC) is considered an intriguing and fascinating cardiovascular disease characterized by a transient wall motion abnormality of the left ventricle, affecting more than one coronary artery territory, often in a circumferential apical distribution. Takotsubo cardiomyopathy was discovered by a Japanese cardiovascular expert and classified as acquired primary cardiomyopathy by the American Heart Association (AHA) in 1990 and 2006, respectively. Regardless of the extensive research efforts, its pathophysiology is still unclear; therefore, there are no well-established guidelines specifically for treating and managing TTC patients. Increasing evidence suggests that sympatho-adrenergic stimulation is strongly associated with the pathogenesis of this disease. Under acute stressful conditions, the hyperstimulation of beta-adrenergic receptors (β-ARs) resulting from excessive release of catecholamines induces intracellular kinases capable of phosphorylating and activating “A Disintegrin and Metalloprotease 17” (ADAM17), a type-I transmembrane protease that plays a central role in acute myocardial inflammation and metabolic lipids dysregulation which are the main hallmarks of TTC. However, our understanding of this is limited; hence this concise review provides a comprehensive insight into the key role of ADAM17 in acute myocardial inflammation and metabolic lipids dysregulation during acute stress. Also, how the synergy of ADAM17-induced acute inflammation and lipids dysregulation causes TTC is explained. Finally, potential therapeutic targets for TTC are also discussed.

25 November 2021 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
GAGabriel Komla Adzika
Gabriel Komla Adzika
HHHongjian Hou
Hongjian Hou
AAAdebayo Oluwafemi Adekunle
Adebayo Oluwafemi Adekunle
RRRuqayya Rizvi
Ruqayya Rizvi
JAJoseph Adu-Amankwaah
Joseph Adu-Amankwaah
HSHong Sun
Hong Sun
The increasing incidence of stress-induced cardiomyopathy is due to the complexities of our modern-day lives, which constantly elicit stress responses. Herein, we aimed to explore the therapeutic potential of Amlexanox and Forskolin in promoting the recovery from stress-induced cardiomyopathy. Isoproterenol-induced cardiomyopathy (ICM) models were made, and the following treatment interventions were administered: 5% v/v DMSO as a placebo, Amlexanox (2.5 mg/100 g/day) treatment, Forskolin (0.5 mg/100 g/day), and Amlexanox and Forskolin combination, at their respective aforementioned dosages. The effects of Amlexanox and Forskolin treatment on ICM models were assessed by eletrocardiography and echocardiography. Also, using histological analysis and ELISA, their impact on myocardial architecture and inflammation were ascertained. ICM mice had excessive myocardial fibrosis, hypertrophy, and aggravated LVSDs which were accompanied by massive CD86+ inflammatory cells infiltration. Amlexanox treatment attenuated the myocardial hypertrophy, fibrosis, and inflammation and also slightly improved systolic functions. Meanwhile, forskolin treatment resulted in arrhythmias but significantly enhanced the resolution of myocardial fibrosis and inflammation. Intriguingly, Amlexanox and Forskolin combination demonstrated the most potency at promoting the recovery of the ICM from LVSD by attenuating maladaptive myocardial hypertrophy, fibrosis, and inflammatory responses. Our findings highlight the Amlexanox and Forskolin combination as a potential therapeutic intervention for enhancing cardiac function recovery from stress-induced cardiomyopathy by promoting the resolution of maladaptive cardiac remodeling.

19 November 2025 in Cardiovascular Research
Verified
Journal Article
Closed access
MNMarie Louise Ndzie Noah
Marie Louise Ndzie Noah
JYJun Yoshioka
Jun Yoshioka